Ross River virus: molecular and cellular aspects of disease pathogenesis

Ross River virus (RRV) is a mosquito-borne alphavirus indigenous to Australia and the Western Pacific region and is responsible for several thousand cases of human RRV disease (RRVD) per annum. The disease primarily involves polyarthritis/arthralgia, with many patients also presenting with rash, mya...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) 2005-09, Vol.107 (3), p.329-342
Main Authors: Rulli, Nestor E, Suhrbier, Andreas, Hueston, Linda, Heise, Mark T, Tupanceska, Daniela, Zaid, Ali, Wilmes, Anja, Gilmore, Kerry, Lidbury, Brett A, Mahalingam, Surendran
Format: Article
Language:English
Subjects:
Alphavirus Infections - drug therapy
Alphavirus Infections - epidemiology
Alphavirus Infections - immunology
Alphavirus Infections - physiopathology
Animals
Antibody Formation
Australia - epidemiology
Disease Models, Animal
Humans
Incidence
Inflammation
Macrophages
Mice
Pacific Islands - epidemiology
Ross River virus - pathogenicity
T-Lymphocytes
Viral Load
Viral Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ross River virus (RRV) is a mosquito-borne alphavirus indigenous to Australia and the Western Pacific region and is responsible for several thousand cases of human RRV disease (RRVD) per annum. The disease primarily involves polyarthritis/arthralgia, with many patients also presenting with rash, myalgia, fever, and/or lethargy. The symptoms can be debilitating at onset, but they usually resolve within 3-6 months. Recent insights into the RRV-host relationship, associated pathology, and molecular biology of infection have generated a number of potential avenues for improved treatment. Although vaccine development has been proposed, the small market size and potential for antibody-dependent enhancement (ADE) of disease make this approach unattractive. Recent insights into the molecular basis of RRV-ADE and the virus's ability to manipulate host inflammatory and immune responses create potential new opportunities for therapeutic invention. Such interventions should overcome virus-induced dysregulation of protective host responses to promote viral clearance and/or ameliorate inflammatory immunopathology.
ISSN:0163-7258
DOI:10.1016/j.pharmthera.2005.03.006